Prosensa Debuts On The Nasdaq Hours After Getting Breakthrough Designation For Lead Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
The Dutch biotech raised $78 million in an initial public offering, peaking investors’ interest with a breakthrough designation for its lead drug candidate, partnered with GSK.
You may also be interested in...
Rare Form: GSK, NEA Back Orphan Disease Venture Fund
A new fund offering access to European translational research focused on rare diseases has high-profile backers and reunites key players in the successful Prosensa IPO.
Duchenne Muscular Dystrophy: Pipeline And Partnering Snapshot
A full pipeline of symptomatic and disease-modifying treatments for Duchenne will transform a long dormant orphan market into a hotly contested commercial prize. But some issues, foremost the scarcity of trial patients, threaten to stall progress in the field.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.